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ABSTRACT
Diabetic peripheral neuropathy (DPN) is a
major sequela of diabetes mellitus and may
have a detrimental effect on the gait of people
with this complication. DPN causes a disruption
in the body’s sensorimotor system and is
believed to affect up to 50% of patients with
diabetes mellitus, dependent on the duration of
diabetes. It has a major effect on morbidity and
mortality. The peripheral nervous system con-
trols the complex series of events in gait
through somatic and autonomic functions,
careful balancing of eccentric and concentric
muscle contractions and a reliance on the sen-
sory information received from the planter
surface. In this literature review focussing on
kinetics, kinematics and posture during gait in
DPN patients, we have identified an intimate
link between DPN and abnormalities in gait and
demonstrated an increased risk in falls for older
patients with diabetes. As such, we have iden-
tified a need for further research on the role of
gait abnormalities in the development of dia-
betic foot ulceration and subsequent
amputations.
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INTRODUCTION
Diabetic peripheral neuropathy (DPN) is a
symmetrical, length-dependent sensorimotor
polyneuropathy which is attributed to meta-
bolic and microvessel alterations due to hyper-
glycaemia and concomitant cardiovascular risk
covariates [1]. The occurrence of other diabetic
microvascular complications in a given patient
strengthens the case that DPN is attributable to
diabetes [1]. The prevalence of DPN in diabetes
can be as high as 50% dependent on age and
duration of diabetes [2], and symptomatic
painful DPN can affect up to 30% of diabetic
patients with neuropathy [3]. Traditionally,
DPN symptoms can be either positive (aching,
burning, sharp or pressure pains) or negative
(numbness or dead feeling), or both simultane-
ously. Although, DPN affects the sensory, motor
and autonomic components of the nervous
system, manifesting as a loss of protective sen-
sation, intrinsic foot muscle dysfunction may
lead to an alteration in gait [4].
Normal walking is the end-product of a
healthy neuro–musculo–skeletal system, which
requires both sensory input to modify learned
motor patterns and muscular output to execute
the desired action. Walking is a critical com-
ponent of physical function. An intact central
and peripheral nervous system to initiate and
control the movement, adequate muscle
strength and bones and joints moving in full
range are essential for normal locomotion,
which is the most natural daily activity for
humans. Moreover, the majority of falls occur
during situations in which the individual is
walking [5]. Hence, DPN may have a significant
interplay with gait disorders and the risk of falls
[6].
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
PATHOPHYSIOLOGY OF DPN
The pathogenesis of DPN is yet to be fully elu-
cidated. The pathological changes are mediated
through competing or parallel pathways:
glucose-induced activation of protein kinase C
isoforms; increased formation of advanced-gly-
cation end-products; increased glucose flux
through the aldose reductase pathway [7–9].
Both metabolic and microvascular factors play
important roles [10, 11].
PREVALENCE OF DPN
The prevalence of DPN is thought to be around
50% [2, 12] and increases with a longer duration
of the disease and poor glycaemic control [13].
When diabetes has been present for [25 years
the prevalence rises to approximately 50% [12].
The Rochester Diabetic Neuropathy Study
reported a prevalence of 54 and 45% for
patients with type 1 and type 2 diabetes mellitus
(T1DM, T2DM), respectively, among 380
patients, with the majority not exhibiting neu-
ropathic symptoms [14]. The 1989 National
Health Interview Survey consisted of a repre-
sentative sample of 84,572 persons in the USA
aged C18 years [15]. Those with diabetes melli-
tus (n = 2405) were identified and asked to
complete a questionnaire to define the preva-
lence of symptoms of sensory neuropathy,
which was found to be 30.2% among subjects
with T1DM. Symptoms of sensory neuropathy
affect 30–40% of diabetic patients, and the
prevalence of these symptoms increases with
longer duration of diabetes, with hypertension
and hyperglycaemia with motor involvement
being more pronounced in those with a longer
duration of diabetes [15].
GAIT
Gait is the forward propulsion of the human
skeleton through a series of movements. One
gait cycle is measured from heel-strike to
heel-strike on the ipsilateral side. The gait cycle
consists of 60% stance and 40% swing phase,
with the latter further subdivided into eight
distinct phases. The prerequisites of normal gait
are stability in stance; toe clearance in swing
phase; swing phase pre-positioning; adequate
step length; a good mechanical and metabolic
efficiency. A healthy gait pattern depends on an
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array of biomechanical features that are
orchestrated by the central nervous system for
economy and stability [16]. Gait is a complex
sequence of events that involves both somatic
and autonomic functions. Locomotion involves
a combination of eccentric and concentric
muscular contractions in order to resist gravity
and achieve forward propulsion of the body’s
centre of gravity.
In addition to efferent motor action resulting
in muscular contractions, plantar cutaneous
sensation and joint position sensation are
important factors in standing balance and
ambulation [17–19]. Plantar skin receptors are
sensitive to pressure and vibration. The plantar
surface of the foot is described as a ‘‘sensory
map’’ that provides the central nervous system
with information on the position of the body,
based on the distribution of activated receptors
[20, 21].
MECHANICS OF GAIT
Forward propulsion of the body’s centre of
gravity involves the voluntary contraction of
muscles within the lower limbs and the rest of
the body, including trunk rotation and arm
swinging [22]. Upon heel-strike there is an
eccentric contraction of the tibialis anterior
muscle. During mid-stance the gastro-soleus
complex contracts eccentrically, followed by
contraction concentrically in terminal stance.
The swing phase involves concentric contrac-
tions of the tibialis anterior for adequate ground
clearance. The hamstrings and quadriceps also
play an important role in gait, as do the pro-
prioceptive feedback mechanisms within the
body, in order to maintain both static and
dynamic balance. This is regulated through an
intact central and peripheral nervous system
[23], resulting in a walking gait that can be
modelled as an ‘‘inverted pendulum’’, conserv-
ing about 70% of energy.
STATIC AND DYNAMIC BALANCE
The ability to remain upright involves an intri-
cate sequence of motor and sensory feedback
mechanisms. Sensory detection of the body in
space from visual, vestibular, proprioceptive
and auditory cues provide feedback to allow
autonomous mechanical adjustments in pos-
ture [24, 25]. Stresses and strains within the
plantar foot activate various mechanoreceptors.
The perception of a limb position and move-
ment is mediated via muscle spindle, cutaneous
and joint receptors. Furthermore, the proprio-
ceptive feedback of muscular contraction is
mediated by tendon organ receptors [26]. This
creates a feedback loop using Ab myelinated
fibres via the dorsal root ganglia to the nuclei
gracilis within the brainstem [27, 28]. In a
recent study by Almurdhi et al. [29], people
with impaired glucose tolerance, but not those
with T2DM, had a significantly higher dynamic
mediolateral sway during walking, suggesting
alterations in gait may occur very early, even in
the pre-diabetes phase.
DIABETIC NEUROPATHY AND GAIT
DISORDERS
This section addresses the changes in gait
associated with diabetic neuropathy and eval-
uates factors that contribute to the develop-
ment of diabetic foot ulcers. Numerous
abnormalities, including sensory loss (impaired
vibration and protective sensation), decreased
lower-extremity strength (force-producing
capacity) and alterations in the central nervous
system contribute to impaired gait in diabetes
[30–33].
Abnormalities in gait have an effect on
patients beyond simple functional impair-
ments. For example, Vileikyte et al. demon-
strated that unsteadiness in gait was the
strongest association with symptoms of
depression in patients with diabetes [34]. Fur-
thermore, both mood and cognition may alter
the relationship between diabetes and gait [35].
People with diabetic neuropathy are at far
greater risk of falling than those with intact
sensation [36, 37]. That most falls occur during
locomotion [36, 38] suggests that these patients
may have difficulty maintaining dynamic sta-
bility while walking. In one study these patients
showed greater deviation of their central mass
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from the centre of pressure during staircase and
level walking [39]. It has been suggested that
sensory feedback may play a pivotal role in
smoothing unintended irregularities that occur
during unperturbed movements [40] and in
adjusting step-to-step limb trajectories to
maintain balance during locomotion [41]. In a
study assessing autonomic function in relation
to gait, people with diabetes took additional
steps when walking in a linear path and during
turns [30]. Reduced walking speed, cadence and
step length and fewer acceleration patterns have
been noted in subjects with diabetic neuropa-
thy [32]. To our knowledge only one previous
non-interventional study has assessed painful
diabetic neuropathy and gait [42]. The authors
of this study concluded that people with painful
diabetic neuropathy had greater variation in
step length and step velocity but also tended to
walk more [42]. The painful diabetic neuropa-
thy group also self-reported an increased num-
ber of falls with subsequent hospitalisations for
injuries sustained, as well as a greater fear of
falling [42]. However, the method used to
analyse gait in this study was a portable device
attached to the patient; thus, the complexities
of alterations in gait strategy in patients with
painful diabetic neuropathy were not fully elu-
cidated [42]. Furthermore, the authors did not
investigate any associations/relationships
between painful diabetic neuropathy and qual-
ity of life and depression, despite the patients
report this increased fear of falling [42]. Inter-
estingly, in another study, intervention with
pregabalin in painful diabetic neuropathy did
not improve gait stability of the patients; rather,
it caused increasing variability in gait speed and
step length [43], possibly reflecting a higher risk
of falling.
Individuals with DPN walk slower than
age-matched healthy controls [32, 44]. Dingwell
et al. [45] and Menz et al. [32] demonstrated
that those with greater DPN-related loss of
plantar cutaneous sensation tended to walk
with a slower preferred walking speed. However,
increases in gait variability are linked to reduc-
tions in self-selected walking speed rather than
sensory loss per se [44]. Gait speed is positively
correlated to survival advantage in the aged
population [46]. Presence of neuropathy has
been shown to be an independent risk factor for
death among patients with diabetes [47].
Diabetic neuropathy is a recognised risk fac-
tor for diabetic foot ulceration [6, 48, 49], and
patients who develop diabetic foot ulceration
are at increased risk of amputation [50, 51]. Foot
amputation is usually the sequela of a cascade of
events, including the development of neuropa-
thy, microangiopathy and vascular disease and
abnormal plantar pressures and gait, all of
which lead to foot ulcers [52]. Once ulceration
is present, the gait may alter further [53], lead-
ing to a self-perpetuating situation of ulcer for-
mation and lack of healing.
There are large variations in the results of
studies addressing these aspects of DPN due to
the heterogeneous population and small num-
bers of subjects enrolled.
KINEMATICS
Locomotion is a fundamental component of
many activities that are critical to the mainte-
nance of an independent lifestyle. Dynamic gait
evaluation allows examination of the intrinsic
and extrinsic factors affecting an individual’s
ability to walk or run. The aim of this section is
to identify specific differences in lower limb
kinematics between patients with diabetic
neuropathy and non-diabetic patients.
The range of movement at joints is altered in
diabetes, and patients with DPN have a reduced
motion at the ankle in dorsiflexion and plantar
flexion and a reduced range of motion at the
knee in both flexion and extension compared to
non-diabetic individuals [54, 55]. Alterations in
ankle joint motion and mobility occur in rela-
tion to plantar pressure changes [56]. The range
of motion at the metatarsal heads is reduced in
patients with DPN when compared to that in
non-diabetic patients [57]. This reduction has
been found to be most prominent at the first
metatarsophalangeal joint in diabetic patients
with a history of ulceration [58, 59].
A relatively increased magnitude of stride-
to-stride variability and decreased magnitude of
local instability are viewed as impairments
because of their association with aging and
disease [45, 60]. The impact of diabetic
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neuropathy on the range of motion at the hip is
unclear. Gomes et al. [61] found an increase in
flexion at the hip in patients with DPN, which
they believed was due to a compensatory effect
for the loss of motion at distal joints. However,
two studies by Raspovic et al. [58] and Yavuzer
et al. [62] found a decrease in the range of hip
flexion in patients with DPN when compared
with non-diabetic individuals.
Interestingly, Hazari et al. [54] recently
found no significant difference between the
range of motion at the hip, knee or ankle joints
when comparing patients with and without
diabetic neuropathy. These authors reported
that the passive range of motion at the ankle
joint complex during gait differed between
diabetic patients and non-diabetic patients.
However, there were no differences between
patients with and without DPN during gait; nor
were there differences in the range of motion of
the ankle joint complex in the three groups
during gait. The glycation of collagen may lead
to periarticular structures becoming thickened
and may confound differences in ankle motion
due to neuropathy [59].
There are only a few studies that compare
kinematics in patients with DPN to patients
without DPN. Those that do have small sample
sizes, and there is a significant variation in
results between them [58, 61, 62]. Larger, more
robust studies are therefore required to identify
if there are any specific kinematic changes due
to neuropathy.
KINETICS
Kinetics looks at the forces involved in the gait
cycle; in this case ground reaction forces and
joint moments.
Ground reaction forces seem to differ
between patients with DPN, without DPN and
controls at either the initial contact or toe-off
stage of gait [54, 55]. However, available studies
are limited by small sample sizes, and there is
considerable variation among the findings.
Based on the limited data currently available,
ground reaction forces do not appear to differ in
the purely diabetic neuropathic gait [54, 55].
However, in a recent cross-sectional case control
study of those with DPN and a cerebrovascular
accident, there were alterations of medial–lat-
eral forces of the non-paretic side and vertical
forces of the paretic side in stroke survivors with
DPN compared to stroke survivors without DPN
and healthy controls [63].
There are limited data available on the
moments at the hip or knee. Savelberg et al. [64]
and Yavuzer et al. [62] observed no significant
differences in joint moments at the hip or the
knee when comparing diabetic patients with or
without neuropathy to non-diabetic patients.
Sacco et al. [65] did demonstrate that people
with diabetes have an increased hip flexion
moment at push off and decreased extensor
moment at initial contact when compared to
those without diabetes, but they found no sig-
nificant difference between patients with and
without DPN [56]. Paradoxically, Fernando
et al. [55] showed a decrease in hip flexion
moment and an increase in extensor moment
in patients with DPN. Taken together, these
results show that there is a lack of good evi-
dence to suggest differences in joint moments
at the hip and knee between patients with dia-
betic neuropathy compared to healthy individ-
uals and those with and without DPN [54].
Peak plantar flexion moments are reduced in
patients with DPN [62, 66, 67]. Savelberg et al.
showed that abnormal plantar pressure patterns
are associated with a redistribution of joint
moments in those with DPN and a conse-
quently reduced capacity to control forward
velocity at heel-strike [68]. However, there are a
paucity of data comparing patients with and
without DPN.
MUSCLE STRENGTH
Sarcopenia is atrophy and progressive loss of
function of skeletal muscle associated with
aging and there is clear evidence that states of
hyperglycaemia accelerate this loss in muscle
size [69] and strength [70].
Previous studies of muscle strength (assessed
through use of a dynamometer) in DPN have
shown reduced power including plantar flexor
torque [71] and reduced ankle and knee maxi-
mal isokinetic muscle strength [72].
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In relation to muscle size, of the intrinsic foot
muscles can be quite pronounced in DPN and
appears to be related to the severity of neuropa-
thy [73–75]. Muscular atrophy is thought to
underlie motor weakness at the ankle in patients
with DPN [74]. The atrophy is most pronounced
in distal muscles of the lower leg indicating a
length dependent neuropathic process [74]. In a
follow up study by Andreassen et al. [76], muscle
atrophy in long-term DPN occurred early in the
feet, progressed steadily up the lower legs and was
related to the severity of neuropathy leading to
weakness at the ankle. Recently, Almurdhi et al.
[77], showed that patients with type 2 diabetes
have a significant reduction in proximal and
distal leg muscle strength and a proximal reduc-
tion in muscle volume, not seen in the distal
muscles due an increase in intramuscular fat.
Furthermore, in a case–control study patients
with DPN possessed less endurance than con-
trols, and a failure of neuromuscular transmis-
sion may have contributed to greater muscle
fatigability [78]. People with DPN have also
demonstrated decreased muscle strength and
slower dorsiflexion contractile properties for
both evoked and voluntary contractions which
may contribute to reduced muscle quality as well
as contractile slowing [79].
PLANTAR PRESSURES
Compensatory musculoskeletal mechanisms
may develop in patients with DPN to compen-
sate for their sensory deficits and in part may
lead to altered plantar pressures. Diabetic neu-
ropathy causes atrophy of the small muscles in
the foot, leading to a loss of support surface and
an increase in bony prominences. These chan-
ges are thought to result in higher peak plantar
pressures at the mid-foot and forefoot when
compared to patients with and without DPN
[49, 50, 54, 55, 80]. There are conflicting data
for peak plantar pressure at the hind foot. Fer-
nando et al. [55] found a significant increase in
peak plantar pressure at the hind foot, but the
more recent meta-analysis by Hazari et al. [54]
found no significant difference.
Other factors that have been identified to
cause a raised plantar pressure are the
development of hallux valgus and hallux rigi-
dus deformities, which cause increased pres-
sures in the medial forefoot. Although intrinsic
muscular foot atrophy does not necessarily
imply foot deformity [75]. A high body mass
index causes increased plantar pressure in the
lateral forefoot which is independent of diabetic
neuropathy [81].
Peak plantar pressure (PPP) is used as a sur-
rogate measure of trauma to the plantar foot.
While mild DPN may not raise plantar pressures
[81], they are clearly elevated in those with
severe DPN [82] and those with obvious foot
deformity [81, 83]. High plantar pressures are a
key risk factor in the development of foot
ulcers, and high foot pressures and neuropathy
are independently associated with ulceration in
patients with diabetes [52]. A foot pressure of
[ 6 N/cm2 is associated with foot ulceration
[52], increased morbidity and an increased risk
of limb amputation [50, 80, 81].
Most research in the field has focused on
assessing plantar pressures before the develop-
ment, or after the healing, of diabetic foot ulcers
[53, 84–87]. The results of these studies suggest
that reducing plantar pressures prevents dia-
betic foot ulcers from occurring and allows
optimal healing if they do develop [88, 89].
Elevated plantar pressures during gait in the
presence of sensory DPN increases plantar tissue
trauma and predisposes people to diabetic foot
ulcers [4, 90]. Previous studies also suggest that
the mechanical loading on the ulcerated limb is
substantially increased during gait [50]. Treat-
ment of diabetic foot ulcer by offloading it
using a total contact cast or removable cast
walker significantly alters the gait and affects
balance, but there is hardly any published lit-
erature in this field.
A more precise formulation of tailored
treatments that include existing recommenda-
tions to reduce plantar pressure in conjunction
with novel interventions to promote changes in
gait may help in the prevention and recurrence
of diabetic foot ulcers. A multi-modal target
strategy is required in the prevention of diabetic
foot ulcers. Future strategies should include an
analysis of gait; however, until biomechanics
laboratories are more widely available in clinical
settings, this remains an unmet need.
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CHARCOT FOOT, PLANTAR
PRESSURES AND GAIT
Charcot neuropathic osteoarthropathy or
‘Charcot foot’ occurs in patients with peripheral
neuropathy, and diabetes is the commonest
cause [91]. It is a process of sensory loss and
inappropriate inflammation in the foot that
causes bone subluxation and dislocation with
bone destruction and new bone formation,
culminating in deformity [92, 93]. The typical
deformity is a mid-foot collapse, often described
as ‘‘rocker-bottom’’ foot.
These deformities cause a rise in PPP and
thereby lead to an increased risk of ulceration
[92, 94, 95]. Studies assessing bone mineral
density as a marker of disease have found an
increased turnover of bone in the affected foot
[95]. This increased turnover is not present in
any other lower limb joint, suggesting that the
inflammatory process that underpins Charcot
foot is a localised phenomenon [96]. The cur-
rent imaging modalities most commonly used
in the diagnosis and management of acute
Charcot foot are X-ray and magnetic resonance
imaging (MRI) [97], with MRI considered to be
superior to X-ray in terms of diagnostics; the
former may show early osteomyelitic changes
[91].
The mainstay of treatment for Charcot foot
involves offloading pressure areas [98]. An
alternative is surgical correction of the defor-
mity, particularly in those with a rocker-bottom
foot; however, a high complication rate of
[ 40% limits wide use of the surgical option
[94]. Offloading pressure areas has been shown
to improve mobilisation when used in con-
junction with orthopaedic shoes [95], and when
undertaken appropriately it achieves limb sal-
vage in 97% of patients [94]. Currently, the data
related to Charcot foot and gait disorders are
limited; therefore, further research is needed.
INTERVENTIONAL STUDIES
ON GAIT DISORDERS IN DIABETES
The focus of interventional studies on patients
with a gait disorder in diabetes has been on
reducing the risk of falls and preventing diabetic
foot ulcer. Aerobic and resistance training
exercise regimes for diabetic patients can
improve gait stability through increased muscle
strength and range of joint motion, as well as
generally improving their blood sugar control,
blood pressure and serum lipid levels
[49, 99–101]. Allet et al. [99] showed that older
individuals with diabetes had impaired balance,
slower reactions and, consequently, a higher
risk of falling than age-matched control sub-
jects. All of these variables improved after
resistance/balance training through a structured
exercise programme. However, the follow-up
period for all studies was relatively short, with
the longest being just 6 months. An exercise
intervention in older people with T2DM with
mild to moderate DPN demonstrated improve-
ments in balance, proprioception, lower-limb
strength, reaction time, and, consequently, a
decreased risk of falling [102]. However, gait was
not specifically assessed in this study [102].
There are a paucity of studies evaluating whe-
ther these improvements in gait are maintained
long term and if they actually reduce the inci-
dence of falls. While a structured exercise pro-
gramme may be beneficial in terms of
physiological function in people with T2DM
and DPN, better-designed longitudinal studies
are required to evaluate the frequency and
duration of any programme and to assess if the
effects are sustainable.
With a view to diabetic ulcer prevention and
treatment, a key in addressing the detrimental
effect of gait disorders in people with diabetes is
the reduction or redistribution of plantar pres-
sure as this is known to be a significant risk
factor in ulcer formation [50, 54, 81, 103].
Redistribution looks at recruiting areas of the
foot or lower leg that are not normally weight
bearing or that are normally under lower pres-
sure in order to redistribute the plantar pressure
across a wider area and, as a result, reduce the
peak pressure in any one area. This can be done
through the application of various insoles, bra-
ces, casts or rigid soles, depending on where the
clinician wishes to transfer the pressure to or
from [50, 103]. Total contact casts are the most
effective method of off-loading plantar pressure
in the presence of an ulcer to aid healing [104].
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Another possible method of reducing plantar
pressures is to reduce gait speed; this strategy has
been shown to reduce the plantar pressures
across the foot [105]. However, in practical terms,
it may be difficult to get patients to consistently
walk slower. Very recent relevant meta-analyses
confirm the limited benefits of reducing gait
speed, but the authors also conclude that larger
studies need to be carried out [54, 55].
CONCLUSIONS
Abnormalities in gait occur in patients with
DPN and are intimately linked to alterations in
kinetics, kinematics and posture. Sarcopenia
related to the severity of DPN also appears to
play a pivotal role. These conditions may lead to
an increased risk of falls and be a significant
cause of morbidity and mortality in older peo-
ple with diabetes. Further detailed evaluation of
gait disorders in DPN is required, particularly in
terms of accurately phenotyping neuropathy in
relation to gait disorders. Further research on
the role of gait abnormalities in the develop-
ment of diabetic foot ulcers and subsequent
amputations needs is urgently required.
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